U.S. Electronic Equipment and Components Stock News

NYSE:NX
NYSE:NXBuilding

A Look At Quanex Building Products (NX) Valuation After New Governance And Tyman Mexico Investigation

Why the new investigation matters for Quanex Building Products (NX) shareholders An investigation into Quanex Building Products (NX) has been launched after allegations that management did not fully disclose underinvestment and equipment issues at its Tyman Mexico facility, raising fresh questions about governance and integration execution. See our latest analysis for Quanex Building Products. Quanex Building Products’ recent 30 day share price return of 22.11% and 90 day share price return...
NYSE:IR
NYSE:IRMachinery

Ingersoll Rand (IR) Margin Compression Tests Bullish Earnings Growth Narratives

Ingersoll Rand (IR) has wrapped up FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.68, alongside trailing twelve month revenue of US$7.7 billion and EPS of US$1.46 that reflect the impact of a one off loss on profitability. The company has seen revenue move from US$1.90 billion and EPS of US$0.57 in Q4 2024 to US$2.1 billion and EPS of US$0.68 in Q4 2025, while trailing net margin has compressed from 11.6% to 7.6% as that US$273.4 million one time hit flows through...
NasdaqGS:PPC
NasdaqGS:PPCFood

Pilgrim's Pride Growth Plans Test Valuation And Earnings Outlook

Pilgrim's Pride is expanding its Just Bare brand and planning new growth projects as it responds to current industry conditions. The company is preparing investments in a new Georgia facility and increasing capital deployment in Mexico. These moves come while Pilgrim's Pride manages challenges such as commodity price swings and pressure on margins. Pilgrim's Pride, traded as NasdaqGS:PPC, is pushing ahead with brand and capacity expansion while its shares trade around $43.32. Over the past...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance

Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates. The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda. These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market. Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh...